A phase 1 study of oral CC5013, an immunomodulatory thalidomide (Thal) derivative, in patients with relapsed and refractory multiple myeloma (MM).
2001
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
31
Citations
NaN
KQI